PMC:7299399 / 22005-22225 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T224","span":{"begin":180,"end":181},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"considered potentially protective) in all eight initial participants across the 25 and 100 μg dose cohorts of the Phase I trial (NCT04283461).70 The company, after having received a fast-track approval from the FDA, is n"}

{"project":"LitCovid-PubTator","denotations":[{"id":"328","span":{"begin":56,"end":68},"obj":"Species"}],"attributes":[{"id":"A328","pred":"tao:has_database_id","subj":"328","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"considered potentially protective) in all eight initial participants across the 25 and 100 μg dose cohorts of the Phase I trial (NCT04283461).70 The company, after having received a fast-track approval from the FDA, is n"}